Leerink Partnrs upgraded shares of Tenax Therapeutics (NASDAQ:TENX – Free Report) to a strong-buy rating in a research report sent to investors on Thursday, Zacks.com reports.
A number of other research analysts have also commented on TENX. Leerink Partners assumed coverage on Tenax Therapeutics in a research report on Thursday. They issued an “outperform” rating and a $16.00 price objective on the stock. StockNews.com assumed coverage on Tenax Therapeutics in a research report on Thursday, September 26th. They issued a “sell” rating for the company. Guggenheim initiated coverage on Tenax Therapeutics in a report on Monday, October 14th. They set a “buy” rating and a $16.00 price objective for the company. Finally, William Blair assumed coverage on shares of Tenax Therapeutics in a research note on Monday, September 30th. They issued an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $170.67.
View Our Latest Report on Tenax Therapeutics
Tenax Therapeutics Trading Down 0.6 %
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last announced its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.99) by $0.16. Research analysts expect that Tenax Therapeutics will post -6.75 EPS for the current fiscal year.
About Tenax Therapeutics
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Featured Stories
- Five stocks we like better than Tenax Therapeutics
- Using the MarketBeat Dividend Yield Calculator
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Dividend Payout Ratio Calculator
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How to Buy Cheap Stocks Step by Step
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.